铱(III)发光生物传感器检测癌症生物标志物:从分子设计到临床转化
本综述评估了环金属化铱(III)配合物发光生物传感器在癌症生物标志物检测中的应用,涵盖其克服临床肿瘤免疫分析限制的特性、对血清肿瘤标志物、循环核酸和外泌体生物标志物的检测能力,以及临床转化面临的障碍和转化路线图。
要点
- 铱(III)配合物的d6电子构型可实现时间门控检测抑制自荧光,发射波长450-800 nm可调以避开血红蛋白吸收干扰。
- 电化学发光信号无需外部光激发即可产生,显著降低复杂生物基质中的背景信号。
- 可检测attomol/L和fmol/L浓度的血清肿瘤标志物、循环核酸和外泌体生物标志物。
核心结论
- 铱(III)发光生物传感器在癌症生物标志物检测中具有克服现有临床免疫分析限制的潜力,但临床转化仍面临多重障碍。
研究设计与样本
- 综述评估了铱(III)发光生物传感器在临床化学和诊断实验室医学中的应用,并基于CLSI验证和ISO计量标准与现有临床免疫分析基准进行比较。
主要发现
- 铱(III)的d6电子构型促进自旋轨道耦合系间窜越至三重态金属-配体电荷转移激发态,用于时间门控检测抑制自荧光。
- 发射波长450-800 nm可调,避免与血红蛋白吸收光谱重叠。
- 共反应物介导的电极反应产生ECL信号,无需外部光激发物种,显著降低背景信号。
- 利用MOF/COF支架掺杂发光体、自增强分子内ECL试剂和纳米材料放大检测级联,可检测attomol/L和fmol/L浓度的血清肿瘤标志物、循环核酸和外泌体生物标志物。
关键数值与推荐
- 与Roche Elecsys和Abbott Architect等临床免疫分析基准进行比较,基于CLSI验证和ISO计量标准评估分析性能。
临床怎么用
- 铱(III)发光生物传感器可用于精准肿瘤学中的癌症生物标志物检测,但需解决内源性基质干扰、制造重现性、细胞毒性和生物相容性、ISO 15189合规及FDA和欧洲IVDR 2017/746监管框架等转化障碍。
局限性
- 内源性基质干扰、制造重现性、铱(III)配合物的细胞毒性和生物相容性、ISO 15189合规以及IVD监管框架是主要转化障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cyclometalated iridium (III) [Ir(III)] complexes are a new generation of octahedral d6 transition metal-based emissive species that exhibit characteristics that overcome important analytical constraints that are present within existing clinical oncology immunoassay systems. This review evaluates Ir(III) luminescent biosensors for the detection of cancer biomarkers, considering their applications in clinical chemistry and diagnostic laboratory medicine. The d6 electronic configuration of iridium facilitates efficient spin-orbit coupled intersystem crossing to the low-lying triplet metal-to-ligand charge transfer excited states. Consequently, this property can be utilized to suppress autofluorescence in time-gated detection formats. The ligand system can be modified systematically and the emission wavelengths (450-800 nm) can be adjusted to avoid spectral overlaps with hemoglobin absorption interference in blood-based samples. In complex biological matrices, with co-reactant mediated electrode reaction, ECL signals are generated without any external photoexcited species to induce background signal, which significantly reduces background signal. Tumor markers in serum, circulating nucleic acids, and exosomal biomarkers at attomol/L and fmol/L concentrations can be detected using MOF/COF scaffold-doped luminophores, self-enhanced intramolecular ECL reagents, and nanomaterial-amplified detection cascades. Translation barriers, such as endogenous matrix interference, manufacturing reproducibility, cytotoxicity and biocompatibility of Ir(III) complexes, compliance with ISO 15189, and IVD regulatory considerations through the FDA and European IVDR 2017/746 frameworks, are highly evaluated. It critically evaluates the reported analytical performance against established clinical immunoassay benchmarks (e.g., Roche Elecsys, Abbott Architect) based on the CLSI validation and ISO metrology standards. Additionally, it outlines a translational roadmap with defined technological readiness milestones for implementing these biosensors in clinical laboratories, particularly in precision oncology.
引用
- Khan NH, Godara A, Afzal M, et al. Iridium(III)-based luminescent biosensors for cancer biomarker detection: From molecular design to clinical translation. Clin Chim Acta. 2026. PMID: 42184864. doi:10.1016/j.cca.2026.121111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。